Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03), FiscalAI reports. Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative return on equity of 89.36%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.84 million.
Here are the key takeaways from Lineage Cell Therapeutics’ conference call:
- Cash runway extended into Q3 2028: Lineage reported $50.8 million in cash, cash equivalents, and marketable securities, aided by a $4.6 million ATM raise. The company also cited potential additional funding from warrant exercises, Roche milestones, and future partnerships.
- OpRegen remains dependent on Roche/Genentech optimization work, particularly surgical delivery for the GAlette study, before a potential multicenter controlled trial. Lineage pointed to expanded study sites, EMA IRIS registration, and Roche’s conference activity as encouraging signals, but acknowledged these steps do not commit Roche to a European study or advancement.
- Lineage highlighted rapid expansion of its internally owned “Lineage 3.0” pipeline using the AlloSCOPE manufacturing platform. COR1 corneal endothelial cells are entering in vivo testing with initial data targeted by year-end, while the ILT1 diabetes program is focused on solving the large-scale islet manufacturing challenge.
- ReSonance, the auditory neuronal cell therapy partnered with Demant, has completed three engineering runs and its first GMP run, with release testing underway. Demant may fund up to $12 million of preclinical work intended to support an IND and/or CTA filing.
- Second-quarter revenue declined to $1.1 million from $2.8 million a year earlier, while R&D spending increased to $4.8 million as Lineage invested in preclinical programs. Reported net income of $1.5 million was primarily driven by a non-cash gain from warrant remeasurement rather than operating performance.
Lineage Cell Therapeutics Stock Performance
NYSEAMERICAN LCTX traded down $0.01 on Thursday, hitting $1.13. The stock had a trading volume of 711,637 shares, compared to its average volume of 999,886. Lineage Cell Therapeutics has a 52-week low of $0.95 and a 52-week high of $2.09. The company has a market capitalization of $281.71 million, a price-to-earnings ratio of -3.90 and a beta of 1.53. The firm has a 50-day moving average of $1.21 and a 200-day moving average of $1.45.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Lineage Cell Therapeutics
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Jain Global LLC boosted its position in shares of Lineage Cell Therapeutics by 202.3% during the 4th quarter. Jain Global LLC now owns 38,851 shares of the company’s stock valued at $65,000 after acquiring an additional 26,000 shares during the last quarter. Equitable Holdings Inc. purchased a new stake in Lineage Cell Therapeutics in the third quarter valued at approximately $51,000. Jefferies Financial Group Inc. bought a new stake in Lineage Cell Therapeutics during the third quarter valued at approximately $105,000. Raymond James Financial Inc. lifted its position in Lineage Cell Therapeutics by 136.2% during the second quarter. Raymond James Financial Inc. now owns 69,380 shares of the company’s stock valued at $63,000 after purchasing an additional 40,009 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Lineage Cell Therapeutics in the 2nd quarter worth approximately $69,000. Institutional investors own 62.47% of the company’s stock.
Lineage Cell Therapeutics Company Profile
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.
Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.
Featured Stories
- Five stocks we like better than Lineage Cell Therapeutics
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
